Sequential methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients following attempted mupirocin nasal decolonisation showed an increase in mupirocin resistance (MR) from 6.6% to 20%. MR isolates from patients who failed decolonization yielded indistinguishable spa types and carried multiple antimicrobialand antiseptic-resistance genes, which may guide infection control and prevention. Here we describe the development of MR in the mupirocin-treated group, as a secondary outcome. In addition, we present the genotypic and phenotypic analyses of isolates obtained longitudinally during the RCT, correlated with MRSA nasal persistence following attempted decolonization with mupirocin.
3
Eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage minimizes MRSA transmission. 1 ' 2 '
3 Mupirocin is used for nasal decolonization despite increasing mupirocin-resistance (MR), i.e. low-level MR (LLMR) and highlevel MR (HLMR) rates of 1-81%. 4, 5 Among persistent carriers, knowledge of circulating colonizing MRSA clones, resistance genes and antimicrobial susceptibility profiles, might better inform antimicrobial choices for decolonization and treatment.
We recently described a Randomized Controlled Trial (RCT) [CT number 2010-023408-28] in which 50 patients receiving 2% mupirocin for nasal decolonization were compared with 50 patients receiving medical grade honey (MGH). 6 Triclosan (1% body wash) was used for concurrent skin decolonization.
Here we describe the development of MR in the mupirocin-treated group, as a secondary outcome. In addition, we present the genotypic and phenotypic analyses of isolates obtained longitudinally during the RCT, correlated with MRSA nasal persistence following attempted decolonization with mupirocin.
All 50 patients in the mupirocin group were known MRSA carriers and had received at least two courses of mupirocin prior to study enrolment. Forty-four patients (44/50) completed the protocol. Of these, 20 received one additional course, and 24 received two additional courses of mupirocin during the study. A single course comprised the application of mupirocin three times a day for five consecutive days.
Isolates were obtained from patients' when recruited, and from persistent carriers within four weeks of completing mupirocin decolonization treatment. however a two fold increase in MR from recruitment to study end following mupirocin exposure was observed.
The increase in MR-MRSA among nasally colonized patients treated with mupirocin from 10% to 20% supports previous findings that mupirocin use strongly correlates with acquisition of MR. 7 ' 8 Our findings in this longitudinal study confirm those in a simulation model in two London hospitals, where MR among MRSA was 9.1%, when a 'screen and treat' policy (similar to our hospital) was implemented, but increased to 21.3% with subsequent universal mupirocin use. 9 The findings reaffirm the importance of active surveillance and routine mupirocin susceptibility testing regardless of suppression therapy, as well as targeted or universal decolonization.
Further characterisation of MRSA isolates from the 19 patients with persistent carriage after mupirocin nasal decolonisation was undertaken using spa typing and DNA microarray analysis. The protocols and primers described by SeqNet 
